[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
The influence of clofibrate and benzafibrate on total serum cholesterol and triglyceride level was investigated in patients with primary hyperlipoproteinaemia type IIa (16 patients) and IIb (13 patients), following a double-blind protocol. A significant decrease of the triglyceride level in the blood serum was stated in patients with hyperlipoproteinaemia type IIb, treated by benzafibrate. From the results presented in this paper it seems that benzafibrate is especially suitable for the treatment of hyperlipoproteinaemias, characterized by hypertriglyceridaemia.
D000328:Adult; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate
Vergleich der Lipidsenker Klofibrat und Bezafibrat bei patienten mit Hyperlipoproteinämie IIa und IIb.